Skip to main navigation
Skip to search
Skip to main content
Fox Chase Cancer Center Home
Help & FAQ
Home
Profiles
Research Units
Research Resources
Research Outputs
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Secondary surgical cytoreduction for recurrent ovarian cancer
University of Texas MD Anderson Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
242
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Secondary surgical cytoreduction for recurrent ovarian cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Chemotherapy
100%
Recurrent Ovarian Cancer
100%
Patient
77%
Surgery
77%
Platinum
77%
Overall Survival
33%
Bevacizumab
33%
Death
22%
Hazard Ratio
22%
Carboplatin
22%
Malignant Neoplasm
11%
Combination Therapy
11%
Woman
11%
Disease
11%
Adjustment
11%
Follow up
11%
Gemcitabine
11%
Quality of Life
11%
Disease Exacerbation
11%
Adjuvant Chemotherapy
11%
Morbidity
11%
Progression Free Survival
11%
Paclitaxel
11%
Ovarian Cancer
11%
Postoperative Complication
11%
Minimal Residual Disease
11%
Fallopian Tube
11%